Biphasic Temporal Relationship between Cancers and Systemic Sclerosis: A Clinical Series from Montpellier University Hospital and Review of the Literature

Archive ouverte

Maria, Alexandre Thibault Jacques | Partouche, Léo | Goulabchand, Radjiv | Rivière, Sophie | Jorgensen, Christian | Rigau, Valérie | Bourgier, Céline | Bessis, Didier | Le Quellec, Alain | Quere, Isabelle | Morel, Jacques | Guilpain, Philippe

Edité par CCSD ; MDPI -

International audience. Cancer among patients with systemic sclerosis (SSc) would appear to be more prevalent than in the general population. Pathophysiological hypotheses are multiple, involving intertwined factors such as immune system antitumoral response, oxygen species dysregulation, and immunosuppressive treatments. We aimed to identify SSc patients with cancer monitored at our center, describing their clinical and immunological characteristics, such as cancer-specific outcomes. We focused in particular on the temporal relationships between cancer onset and SSc diagnosis. A retrospective study was conducted on SSc patients from Montpellier University Hospital from 2003 to 2018. Clinical characteristics and outcomes of each SSc patient with cancer were recorded. Fifty-five patients with SSc and at least one cancer was included (median age 56 years (47–66)), with a median follow-up time of 11 years (4–15). Sixty-four metachronous malignancies were identified (12 patients had two cancers). Among them, early-onset cancer occurrences (±5 years from SSc diagnosis) included 23 cancers (39% breast cancers, 13% lung cancers, and 13% gastro-intestinal tract cancers). Twenty-two cancers occurred 10 years (±5 years) after SSc diagnosis (14% breast cancers, 23% gastrointestinal (GI) tract cancers, and 18% lung cancers). Patients without any of the two autoantibodies (anti-centromere (ACA) and anti-topoisomerase (ATA-scl70) antibodies) were more prevalent in the early-onset cancer subgroup (14 vs. 6, p = 0.02). This study brought to light two peaks of cancer occurrence in SSc patients. Early-onset cancers were associated with SSc with a specific immunological signature. Late-onset cancers might be the consequence of a subtle interplay between repeated target organ inflammation, immunosuppressant use, mesenchymal cell dysfunction and subsequent genetic alterations.

Suggestions

Du même auteur

Cellular therapy for autoimmune diseases: Beyond autologous hematopoietic stem cell transplantation. Thérapie cellulaire des maladies auto-immunes : au-delà de l’autogreffe

Archive ouverte | Maria, Alexandre Thibault Jacques | CCSD

International audience. Beyond autologous hematopoietic stem cell transplantation, an approach validated for the treatment of refractory multiple sclerosis and systemic sclerosis, cell therapy approaches based on th...

Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors

Archive ouverte | Maria, Alexandre Thibault Jacques | CCSD

International audience. Systemic sclerosis (SSc) is an autoimmune connective tissue disorder, characterized by multisystem involvement, vasculopathy, and fibrosis. An increased risk of malignancy is observed in SSc ...

Adult onset Still's disease (AOSD) in the era of biologic therapies: Dichotomous view for cytokine and clinical expressions

Archive ouverte | Maria, Alexandre Thibault Jacques | CCSD

International audience. Adult onset Still's disease (AOSD) is a rare inflammatory disorder characterized by hectic spiking fever, evanescent rash and joint involvement. Prognosis is highly variable upon disease cour...

Chargement des enrichissements...